Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 23, Issue 8, Pages 872-878Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2013.04.002
Keywords
First-generation antipsychotics (FGA); Second-generation antipsychotics (SGA); Hyperprolactinemia; Dose-response relationship; Anticholinergics; Schizophrenia
Funding
- H. Lundbeck
- Pfizer
- Chempaq
- Bristol-Myers Squibb
- Astra Zeneca
- Lundbeck
- Janssen-Cilag
- Hemocue
- Eli-Lilly
Ask authors/readers for more resources
In a nationwide study using linkage of Danish hospital registers we examined predictors of hip fracture (ICD-10: S72) in 15,431 patients with schizophrenia (ICD-10: F20 or ICD-8: 295) and 3,807,597 population controls. Shorter education, disability pension, lifetime alcohol abuse, somatic co-morbidity, antipsychotics (IRR=1.19; 95% Cl 1.15-1.24), antidepressant (IRR=1.18; 95% Cl 1.16-1.20), anticholinergics (IRR=1.29; 95% CI 1.22-1.36), benzodiazepines (IRR=1.06; 95% CI 1.04-1.08) and corticosteroids (IRR=1.44; 95% CI 1.36-1.53) were significant predictors. In 556 persons with schizophrenia and hip fracture (matched to 1:3 to schizophrenia controls without hip fracture), antipsychotic polypharmacy predicted hip fracture. Analyses among antipsychotic monotherapy patients showed no differential effect of individual antipsychotics. A dose-response relationship of hip fracture and lifetime antipsychotics consumption was found (IRR=1.13 95% CI 1.07-1.19) and both prolactin-increasing and non-prolactin-increasing antipsychotics contributed to the effect. In conclusion, several factors, including complex psychopharmacological treatment, contribute in the prediction of hip fracture in large populations. Preventive strategies should focus attention to severely ill patients with high likelihood of a receiving complex psychopharmacologic treatment and high doses of antipsychotics. (C) 2013 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available